•
SM
SMMT
Summit Therapeutics Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
12.54B
Volume
3.75M
52W High
$36.91
52W Low
$15.55
Open
$0.00
Prev Close
$16.06
Day Range
0.00 - 0.00
About Summit Therapeutics Inc. Common Stock
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Latest News
Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio?
Benzinga•Jan 18
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
The Motley Fool•Jan 6
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now?
The Motley Fool•Dec 5
Why Wall Street Is Backing These 3 Comeback Stocks
Investing.com•Oct 29
What's Going On With Summit Therapeutics Stock On Monday?
Benzinga•Oct 20
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
GlobeNewswire Inc.•Sep 10
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
GlobeNewswire Inc.•Sep 10
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Benzinga•Sep 8